Merck, Pfizer drug combo extends kidney cancer survival

Nearly 90% of patients who received the combination therapy were still alive after 12 months compared with about 78% of patients who were alive after a year when treated with the older drug Sutent, data showed.

from Hindustan Times - health-fitness http://bit.ly/2DNIOYA
via IFTTT